D iabetes is the number four killer in the United States. It is insidious, not taken seriously, not easily diagnosed, and not easily treated. If uncontrolled, diabetes causes blindness, kidney failure, neuropathy, and cardiovascular complications leading to stroke, amputations, heart attacks, and impotence, among other things. The cost of diabetes in the United States is over $92 billion per year. Direct costs of $45 billion per year account for such items as hospitalizations, physician visits, medications, glucose monitoring supplies, and laboratory work. The indirect cost of about $47 billion per year is represented by such factors as days lost from work, morbidity, and mortality (National Institutes of Health [NIH], 1995) .
Sixteen million Americans, or about 1 in 20 people, have diabetes. It is estimated that 8 million people are undiagnosed (NIH, 1995) . The occupational health nurse has the opportunity to make a major impact on this devastating disease. The majority (80% to 90%) of the people with diabetes are adults with Type II diabetes. This disease primarily occurs in obese, sedentary, middle aged adults with a family history of diabetes. Type II diabetes is primarily a disease of insulin resistance (not insulin deficiency) triggered by obesity. Proactive health care providers are developing and implementing programs for lifestyle interventions targeting weight loss and exercise. If these interventions do not maintain glycemic control, oral medications or insulin may be necessary. Lifestyle strategies may delay or prevent Type II diabetes.
Type I diabetes is an autoimmune disease usually ABOUT THE AUTHOR: Ms. Hentzen is Manager, Diabetes, Via Christi Regional Medical Center, Wichita, KS. FEBRUARY 1997, VOL. 45, NO.2 occuring in preadolescents . It is characterized by weight loss, and often ketoacidosis at the time of diagnosis. The primary treatment difference in Type I is the medication therapy. The person with Type I diabetes is insulin dependent. Because of the insulinopenia, oral agents are contraindicated. Careful attention to meal planning, exercise, and stress management are necessary to balance the time actions of the multiple daily insulin injections. Both types of diabetes exhibit hyperglycemia at the time of diagnosis. If not controlled, over a period of years hyperglycemia contributes to retinopathy, nephropathy, and neuropathy. Managed care, with capitated payment for health care, is challenging health care providers to develop cost effective interventions. Treating nephropathy, end stage renal disease, hypertension, and blindness is very costly. Managed care organizations are realizing the value of prevention. It is most cost effective to delay or prevent diabetes, rather than treat its devastating complications. The occupational health nurse is a pivotal person in the potential prevention of diabetes. Helping implement preventive health care, healthy eating habits, regular exercise, and maintenance of desirable body weight are the keys to prevention of Type II diabetes. Early screening and intervention are additional services the occupational health nurse can provide.
The American Diabetes Association (ADA) is developing recommendation s to test for diabetes in asymptomatic, undiagnosed individuals. Preliminary recommendations include: 1) testing for diabetes should be performed in all individuals at age 45 years and, if normal, should be repeated at 3 year intervals; 2) testing should commence at a younger age, or be carried out more frequently, in individuals who:
• Are obese (> 120% desired body weight or a body mass index [BMI] >27 kg/m"), • Have a first degree relative with diabetes.
• Are members of a high risk ethnic population (i.e., African American, Hispanic, Native American).
• Delivered a baby weighing >9 lb. or who have been diagnosed with gestational diabetes (GDM). • Are hypertensive (>140/90). • Have an HDL-C level <35 mg/dL or a triglyceride level >250 mg/dL. • Have impairedglucosetolerance(lGT) (ADA, 1996b) .
The ADA is proposing not only new screening guidelines, but also new diagnostic criteria: Diagnosis of diabetes may be identified based on any of the following:
1. Symptoms of diabetes and a casual (random) plasma glucose value >200mg/dL. Classic symptoms of diabetes include polyuria, polydypsia, and unexplained weight loss, with glycosuria and ketonuria, or 2. An ADA proposed fasting plasma glucose (FPG) >125mg/dL. Fasting is defined as no caloric intake for at least 10 hours, or 3. The plasma glucose value in the 2 hour sample (2hr PG) of the oral glucose tolerance test (OGGT) is >200 mg/dL. The test should be performed using a load of 75gm of anhydrous glucose. The third measure (OGTT) is not recommended for routine clinical use (ADA, 1996a) .
These guidelines are valuable. However, many adults at risk may have high blood glucose and unremarkable symptoms, thus making the screening and consequent diagnosis difficult. Adults may have blurry vision, fatigue, and frequent (yeast) infections-early symptoms of diabetes. Fatigue and the necessity of using bifocals plague many middle adults. These symptoms are often attributed to the aging process, rather than diabetes. It is not uncommon for people to have some evidence of the complications of diabetes (peripheral neuropathy or background retinopathy) at the time of diagnosis.
Avoiding the complications of diabetes has been paramount since the landmark Diabetes Control and Complications Trial (DCCT). This 10 year, prospective trial looked at the relationship between elevated blood sugars and complications of diabetes. Over 1,440 people with Type I diabetes followed either conventional (1 to 2 shots/day, urine testing or blood glucose testing, and standard health care contact) or intensive (3 to 4 shots/day or the insulin pump, blood glucose testing 4+ times/day, and frequent health care contact) management (DCCT, 1993) .
The data were so dramatic the study was interrupted in its ninth year. The measure of glycemic control used was the hemoglobin AIC (Hbg AlC). This blood test provides an average measurement for the past 2 to 3 months of blood glucose. The upper limit of normal is 6%. This roughly translates to an average blood glucose in the range of 120mg/dL. Conventional management participants maintained an AlC of about 9% over the course of the 94 study, while the intensively controlled group maintained an average of 7% Ale. The results showed the intensive group with "near normal" blood glucose had a reduction in (three step progression) retinopathy of 76%. Reduction in complications of nephropathy and neuropathy were >60% and > 50%, respectively. Long term complications of Type I diabetes are clearly related to elevated blood glucose. Experts also believe elevated blood glucose leads to long term complications in Type II diabetes.
The challenge for clinicians is to help individuals with diabetes maintain near normal blood glucose. The ADA recommends taking action with the health management plan if the fasting glucose exceeds 140mgldL, random glucose exceeds 180mg/dL, or the Hbg AlC exceeds 8%. Many clinicians use the following management goals (ADA, 1996a): • Fasting glucose < 120mgldL.
• 2 hour post-prandial < 150mg/dL. • Hbg AIC < 7%.
MANAGEMENT OF TYPE II DIABETES
The primary goal of diabetes management is normal blood glucose. Because of the pathology of insulin resistance in Type II, this goal can be obtained with lifestyle modifications of meal planning, with resultant weight loss, and exercise.
Medical Nutrition Therapy
Referral to a dietitian for medical nutrition therapy is ideal. As part of the nutrition assessment a basal energy expenditure (BEE) may be done, which addresses height, weight, and activity level. Determining calorie levels is difficult. If the BEE formula cannot be performed, the following guideline is suggested by the ADA ( The nutrition guidelines for all people with diabetes are described in the Sidebar.
In clinical practice, many methods are used to help people distribute calories and attain well balanced meals. The Exchange Method, Point System, and Carbohydrate Counting are some of the methods used. The Exchange Lists were developed by the American Diabetes Association in conjunction with the American Dietetic Association. Six groups are listed: fruit, starch (breads and cere-als), milk, fat, meat (high, medium, and lean fat), and vegetables. Carbohydrate counting is a method used to count carbohydrate grams and match that to available insulin. It has begun to be used in recent years with intensive insulin therapy. The Calorie Point system is a method of counting (all) calories. Seventy-five calories equal 1 point. The points are distributed in three meals and usually three snacks, allowing people to choose which foods they eat with more flexibility. The Food Guide Pyramid is a model used to teach healthy eating concepts. Food intake needs to be matched to peak times of insulin and oral agents. Timing is one issue; however, portion size is another. Both must be carefully balanced.
Concern about sucrose in the diet remains, in spite of several research studies that indicate no adverse glycemic effect (Bantle, 1993; Loghan, 1991) . If people with diabetes do glucose monitoring 1 to 2 hours after ingesting sucrose, they can individually determine the effect of sugar on their glucose profile. Moderate amounts of sugar with a mixed meal will undoubtedly blunt the glycemic spike.
The number one cause of death for all people remains cardiovascular problems. For people with uncontrolled diabetes, its process is accelerated. Elevated blood glucose is a precursor to elevated triglycerides. The person with diabetes needs to strive for normal lipid levels. Reducing fat intake in the diet is an important strategy.
Activity
Sweat and torture are not necessary to improve fitness and insulin sensitivity. Moderate exercise three to five times per week for 30 minutes can be as simple as walking. "Exercise grazing" is a concept that shows comparable benefits if the 30 minutes per day is obtained in three separate, 10 minute segments. Intensity of the activity can be determined by calculating target heart rate (220 -age divided by 65% to 80%). Individuals must be capable of monitoring their own pulse. This is not easy and, in some cases of peripheral neuropathy, not possible. Borg's rate of perceived exertion is also used to determine on a scale of I to 10 how intense the activity feels to the person. The exercise intensity should be at about a level of 5. More commonly used is the "sing-talk" test. Individuals should be able to exercise at a level in which they can continue to talk, but not be able to sing with gusto.
Exercise precautions include: • Determining blood glucose level before exercise. • Adding extra snack if blood glucose level is <80 mg/dL before exercise.
• Determining blood glucose level after exercise and adding a snack if needed. FEBRUARY 1997, VOL. 45, NO.2 Nutritional Guidelines for all People with Diabetes* • Protein to provide 10% to 20% of calories «10% for those with nephropathy).
• Saturated fat to provide <10% of calories «7% for those with elevated LDL).
• Polyunsaturated fat to provide <10% of calories.
• Remaining calories to be divided between carbohydrate and monounsaturated fat, based on health needs and personal tolerance. • Use of caloric sweeteners, including sucrose, is acceptable.
• Fiber (20 to 35 glday) and sodium (<300 mglday) levels recommended for the general healthy population.
• Cholesterol limited to <300 mglday.
• Alcohol in moderation for Type II patients, less than 6% of total daily calor ies. 'American Diabetes Association (1996c Other considerations may be indicated. Consulting an exercise physiologist facilitates thorough assessment and development of an exercise prescription.
Medication Therapy
Oral Agents. Several classes of oral agents include sulfonyureas, biguinides (metformin), and alpha glucosidase inhibitors (Precose). The first generation sulfonyureas are still available. However, the second generation agents are more widely used. The third generation sulfonyurea (Amaryl) is now on the market. These agents are not insulin, as many clients believe. However, they do increase endogenous secretion, thus causing the possibility of hypoglycemia, particularly at the peak time of the medication. Additional glycemic improvement is derived from peripheral glucose utilization, and probably some improvement in post-receptor defects. These agents may interact with alcohol, causing the Antabuse (disulfiram) reaction. This is particularly prevalent in people who drink alcohol and take chlorpropamide (Diabinese). Many other side effects are seen with Diabinese, including prolonged hypoglycemia. Drug interactions are most problematic. Therefore, the second or third generation oral agents, Glyburide and Glypizide, are more widely used. They have negligible interactions with other medications, minimal flushing from the Antabuse reaction, and are much more potent. Sulfonyureas may be initiated as monotherapy. When maximal dose is reached, rather than initiate insulin, the new Metforrnin (Glucophage) oral agent may be added to the therapy (DeFronzo, 1995) (see Table I ).
Metformin (Glucophage) initiates an entirely different physiologic response than the sulfonyureas. Many clinicians capitalize on the benefits of both groups of oral agents by prescribing them together. Glucophage targets the insulin resistance problems of Type II diabetes, rather than treating the symptoms. It lowers glucose by suppressing liver glycogen release, improving peripheral glucose utilization, and blocking some glucose absorption from the gut. Consequently, taken as monotherapy it does not cause hypoglycemia . Both liver and kidney function must be checked (Creatanine <1.4 in women and <1.5 in men), prior to initiating the medication. Glucophage has a potential side effect of weight loss (8.4 lb. in 6 months) and improvement of lipids. Therefore, in the healthy, obese client with hypertriglyceridemia, it may be the drug of choice. This drug is a Biguinides (a cousin to the Phenforrnins) and may cause increases in lactate in the client with hypoxic conditions. This may lead to the often fatal lactic acidosis. However, prior to entry of the drug into the United States, studies of mutilple year European drug utilization showed a rare incidence of lactic acidosis. If the client becomes hypoxic (i.e., acute myocardial infarction, chronic obstructive pulmonary disease, pneumonia, surgery), the drug should be stopped. In addition, if the person with diabetes is having contrast dye studies, or consumes alcohol, the drug must be discontinued. Gastrointestinal symptoms are the major client complaint, with diarrhea the most common. Symptom resolution usually occurs in several days.
Acarbose (Precose) is yet another drug for Type II diabetes. This drug targets the intestinal tract specifically, blocking the glucosidase enzyme necessary for carbohydrate absorption. The glucose absorption is slowed after ingestion of a meal. This has some clinical significance for Type II clients who may have lost first phase insulin release. The delay in glucose absorption may allow the available internal insulin to be eventually used, 96 thus blunting the glycemic spike. Flatulence is the major side effect. Clients are started at subclinical doses (25mg tid) in an effort to minimize this problem.
The Food and Drug Administration expert panel has recommended approval of the insulin sensitizer Rezulin (troglitazone). It is expected to be on the market in early 1997. It is currently being used in the NIH Type II Prevention Trial. It will be most effective for clients with IGT and early Type II diabetes.
The pharmacologic agents available for treating Type II diabetes are becoming overwhelming. The clinician must remember that adding another pill adds another $45 to $50/month in health care expenses. The fundamental treatment for Type II diabetes remains diet and exercise. When maximum doses of oral agents are reached, insulin initiation is indicated. Secondary failure occurs in about 10% of the Type II patients per year. About 40% of Type II patients are on insulin (ADA, 1996b) .
Insulin Therapy. Recombinant DNA (rDNA) human insulin has been available since the early 1980s from Lilly (Indianapolis, Ind.) and, in the past several years, from NovoNordisk (Clayton, NC). This synthetically made human insulin reduces antibodies and insulin resistance often seen with animal source insulins. The availability is plentiful, as it is not dependent on slaughter house supply, which was the case with the animal source insulins. Currently, diabetes experts recommend all clients taking insulin, take human insulin. The time actions are divided into four distinct groups; very rapid (LisPro Humalog), rapid acting (Regular), intermediate acting (NPH and Lente), and long acting (Ultralente). One of the most convenient developments in the insulin arena, however, is the advent of pre-set mixtures (70/30: NPHIR and 50150: NPHIR) (see Figure 1) .
Commonly, the person with Type II diabetes may be started on NPH at bedtime in an effort to target liver glycogen release during the night which causes an elevated fasting blood glucose. The client may continue oral agents during the day if euglycemia is maintained. Many insulin protocols allow unique combinations of insulins that are being used today. The insulin can be arranged to allow greater flexibility in eating times and lifestyles. In the 1970s and 1980s the completely insulin dependent person commonly took two injections of mixed insulin NPHIR or 70/30. Currently, it is much more common for clinicians to prescribe multiple dose insulin (MDI) (see Figures 2-3) .
MANAGEMENT OF TYPE I DIABETES
The individual with Type I diabetes has lost endogenous insulin production ability almost from the time of more quickly and may even be absorbed from the buccal mucosa if gastric stasis is present. If 10 to 15 minutes after the initial treatment the blood glucose is not improved, the second treatment may be more effective if the person holds some gel or sugar cubes in the cheek for absorption. When the blood glucose is definitely improving, a snack (with complex carbohydrate or protein) should be provided. Candy is not a good choice for treating hypoglycemia. It is very difficult to eat only the small amount (10 to 15 gm of carbohydrate, 40 to 60 calories) necessary. Severe hypoglycemia will usually not occur until the blood glucose is less than 20 mg. The individual may have a seizure or become unconscious. If the individual is conscious and alert, but it is determined that the person may choke if something is given by mouth, it is crucial not to give anything by mouth. If the occupational health nurse is available and has the legal protocol, D50 intravenous is the treatment of choice. The usual amount given is 20 to 25 cc for the adult and 10 to 15 cc for the child. If an intravenous site is not available or the crisis occurs at home, the treatment should be Glucagon 1 mg, 1M. Children under 5 years should receive 0.5 mg 1M. The Glucagon Emergency Kit is a prescription item that comes with the diluent already drawn up in the syringe. The lipolyzed glucagon tablet must be dissolved and the entire contents injected. Seizure precautions should be implemented. The glucagon triggers the liver to release the glycogen reserves stored there. When the person responds 10 to 15 minutes later, nausea and headache are usually present. This is from the rapid shift in blood sugar and some subsequent cerebral edema. The next step in the treatment may be non-caffeinated regular soda to help calm the stomach. This is followed by a mixed snack to help maintain the blood glucose level. The glycogen reserves may take 8 to 12 hours to replenish in the liver, so adequate caloric intake should occur even if the blood glucose is elevated from the treatment.
SELF MONITORING OF BLOOD GLUCOSE
Self monitoring of blood glucose (SMBG) is recommended by the ADA for all individuals on medication therapy. The current small size and simplicity of the technique makes it "do-able" for almost everyone. The meters start at about $50 with rebates and trade-ins. The cost comes with the purchase of the test strips (about 60 to 80 cents each). The common recommendation is to test four times per day/3 to 4 days per week for insulin dependent clients and four times per day/2 to 3 days per week for non-insulin dependent clients (see Table 2 ).
Costs can quickly accumulate. However, the benefits are great. People with diabetes can now monitor themselves at home, be empowered and in control of their diabetes, experiment with various foods, treat hypoglycemia with accurate data, and actually make insulin, oral agent, activity, and food adjustments themselves. Diabetes is a disease managed by the person with diabetes. The health care provider and health care team essentially serve as consultants to the well educated, motivated person with diabetes.
Current technology in meters allows for ease of use which eliminates many of the user errors commonly seen with first generation meters. The timer is automatically triggered when an adequate blood sample is applied to the strip. The no wipe technique prevents inconsistencies by clients and health professionals in pressure application of the wiping. The automatic reporting of blood glucose and recording into memory of the meter makes the process almost fool proof. The error still seen most commonly is not obtaining an adequate blood sample. While most meters tell the individual the sample is not adequate, the strip has been wasted (and the 75 cents) and the client must start over. Washing the hands in warm water, pretending to "shake down" a thermometer, and milking the finger prior to puncturing it, may result in a more effective sample. Talking meters are available for the blind, thereby promoting independence. Many meters have software packages to help with data management. Pie charts, bar graphs, and weekly summaries are available when data are downloaded into the computer. Average blood glucose levels allow for patterned management by the client, thus increasing independence. Patterned management helps clients look 100 for trends, thus seeing the big picture, and not reacting (or over-reacting) to each blood glucose reading. Corrections in diet, activity, and/or medication use can be made during the time of day before the consistent problem appears.
Glucose monitoring is a critical element in managing diabetes, which should help the person with diabetes prevent devastating complications.
COMPLICATIONS MONITORING
The clinician has a major responsibility in monitoring complications. The guidelines (ADA, 1996b) for care of the person with diabetes are: • Hbg AIC, every 3 months. • Foot examination, every 3 months. • Blood pressure, every 3 months. • Nutrition evaluation, every 3 months. • Education evaluation, every 3 months. • Urine albumin, annually. • Dilated eye examination, annually. • Lipid profile, annually.
SELF MANAGEMENT TRAINING
Diabetes education has evolved from the basic skills of self care to the comprehensive self management training that enhances independence. The basic skills include presenting the meal plan, demonstrating injections, glucose testing, and hypoglycemia treatment. The total teaching process takes about 3 hours. A home management level of education takes about 10 hours. This will allow for demonstration and return demonstration of skills, more topics to be presented, and more depth in content. The self management level of education may take as much as 25 hours total. The delivery may be presented over weeks or months. The insulin adjustment information with relationship among diet, exercise, and medication is the highlight of this level of education.Prerequisites to self management include competent skill performance, sufficient knowledge base, internal motivation, support from care partners and health care professionals, and effective cognitive functioning.
Standards have been in place for self management training since the early 1980s. Recognition criteria have been developed and are reviewed by the ADA. The self review process is peer evaluated. Sections to evaluate faculty credentials, program curriculum, institutional and program support, assessment, follow up, and outcomes exist. The process of recognition is detailed and lengthy, but many diabetes centers are making the effort to complete the process. It is an important indicator of quality for the public. Professional credentialing is available for health professionals specializing in diabetes education. The Certified Diabetes Educator (CDE) is becoming the gold standard for diabetes education programs in the United States. If licensed or registered (i.e., RN, RD, MD) or holding a master's degree in a health related profession and acquiring 2,000 hours in direct patient teaching in a formal program, an individual is eligible to take the CDE examination. The certification must be renewed every 5 years through re-testing .
Recognition and certification programs provide third party carriers, and others involved in reimbursement activities, with documentation to validate that programs meet minimum standards and faculty are appropriately credentialed. These are majo r steps in the growth of the profession and specialty of diabetes management. Current issues relate to the expanded role of diabetes educators. The role has evolved to include clinical management. The American Association of Diabetes Educators is spearheading efforts to define and help credenti al "advanced practice." Collaborative efforts are under way with the American Nurses Association and the American Dietetic Association, their respective practice groups, and credentialing bodies to further delineate these needs (see Sidebar for Resources Available).
Diabetes is a specialty practice. However, 80% of all the people with diabetes are managed by primary care practitioners . Therefore , the burden of providing effective care, conscientiou s education, and complications monitoring falls to all practicing health care professionals. Occupational health nurses have an opportunity to impact the lives of people with diabetes with their skills in assessment, clinical referrals, and reinforcement of sound education principles.
This issue of the AAOHN JOUR-NAL contains a Continuing Education Module on "Diabetes Update," and has been approved by AAOHN for 1 contact hour of continuing education credit upon successful completion of the posttest and evaluation .
A certificate will be awarded and the scored test will be returned when the following requirements are met by the participant: 1) The completed answer sheet is received at AAOHN on or before January 31, 1998; (2) A score of 70% is achieved by the participant ; (3) The answer sheet is accompanied by a $10.00 process ing fee. Expect up to 6 weeks for delivery of the certificate.
Upon complet ion of this lesson, the occupational health nurse will be able to: 1. Differentiate between Type I and Type II diabetes symptoms and causes . 2. Compare pharmacological treatment modalities for Type I and Type II diabetes .
Discuss Self Blood Glucose
Monitor ing concepts for the person with diabetes. 4. Describe nutrition guidel ines for the person with diabetes. AAOHN is accredited as a provider of continuing education in nursing by the American Nurses Credentia ling Cente r's Commission on Accreditation. Alabama provider number ABNP0063. California provider number CEP9283 . Louisiana provider number LSBN3 .
Contact hour credits received for successful completion of the postlest and evaluation may be used for relicensure, certification, or re-certification.
Directions: Circle the letler of the best answer on the answer sheet provided. (Note: you may subm it a photocopy for processing.)
CE MOD U L E

Diabetes Update
1. Which of the following is true about Type II diabetes? A. It is an autoimmune disease that usually occurs in preadolescence. B. A person with Type II diabetes is insulin dependent. C. Lifestyle strategies may prevent Type II diabetes. D. Twenty percent of adults with diabetes have Type II.
